Develops immunotherapies for cancer and autoimmune diseases, focusing on LAG-3 and IMP321 therapies to modulate immune responses.
Immutep Limited, a dynamic biotechnology firm based in Sydney, Australia, specializes in the innovative research and development of pharmaceutical products. The company focuses on advancing immunotherapeutic solutions for the treatment of cancer and autoimmune disorders. At the forefront of its pipeline is eftilagimod alpha (efti or IMP321), a recombinant protein currently undergoing Phase IIb clinical trials as part of a chemo-immunotherapy combination aimed at addressing metastatic breast cancer. Immutep also drives forward TACTI-002, in Phase II trials for head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer, along with TACTI-003, in Phase IIb trials for HNSCC. Additionally, the company is progressing with INSIGHT-003 in Phase I trials for solid tumors, and INSIGHT-005, which is in Phase I/IIa trials targeting solid tumors.
Innovating in autoimmune disease treatments, Immutep offers IMP761, an agonist targeting lymphocyte activation gene 3, and IMP701, an antagonist antibody designed to enhance T cell proliferation in cancer patients. The company also develops IMP731, a depleting antibody that selectively removes T cells implicated in autoimmune responses. Immutep's strategic collaborations with industry leaders such as GlaxoSmithKline, Novartis, Merck & Co., and Merck KGaA, among others, underscore its commitment to advancing therapeutic breakthroughs and expanding treatment options across diverse disease areas.
Founded in 1987 as Prima BioMed Ltd and rebranded as Immutep Limited in November 2017, the company has established itself as a pivotal player in biotechnology. Immutep's headquarters in Sydney serve as a hub for its global operations, driving the development of next-generation therapies that aim to redefine standards of care and improve outcomes for patients worldwide.